Adult Dosing
Overactive bladder
- Start 4 mg PO qd; may increase to 8 mg PO qd. [Max: 8 mg/day]
- If on potent CYP3A4 inhibitors: Max: 4 mg/day
Note: Do not cut/crush/chew tablets. Swallow whole with liquid
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- >30 mL/min: No dose adjustments
- <30 mL/min: Max: 4 mg PO qd
- Hemodialysis: Dose adjustments not defined
Hepatic Dose Adjustment
- Mild to moderate impairment: No dose adjustments
- Severe impairment: Use not recommended
- Antimuscarinic agents, including fesoterodine should be used with caution in patients with decreased gastrointestinal motility, such as those with severe constipation
- Administer with caution in patients with clinically significant bladder outlet obstruction because of risk of urinary retention
- Dosages greater than 4 mg PO qd are not recommended in patients with severe renal insufficiency and in patients taking potent CYP3A4 inhibitors
- Fesoterodine has not been studied in severe hepatic impairment. Use in this population is not recommended
- Fesoterodine can cause constipation, urinary retention and blurred vision
- Heat prostration (due to decreased sweating) can occur if the drug is used in a hot environment
- Anticholinergic central nervous system (CNS) effects such as headache, dizziness, and somnolence may occur with fesoterodine. Monitor for signs of anticholinergic CNS effects, especially after starting treatment or increasing the dose. Counsel patients not to drive or operate heavy machinery after initiating fesoterodine. Consider dose reduction or discontinuation if a patient experiences anticholinergic CNS effects
Cautions: Use cautiously in
- Renal impairment (refer dose adjustment section)
- Gastrointestinal obstructive disorders
- Impaired GI motility
- Myasthenia gravis
- Controlled angle-closure glaucoma (requires careful monitoring; use only if potential benefits outweigh the risk)
- Bladder neck obstruction
- Geriatric patients
- Doses greater than 4 mg are not recommended in patients taking a potent CYP3A4 inhibitor (e.g. ketoconazole, itraconazole, clarithromycin).
- Pregnancy (use only if potential benefit justifies risks to fetus)
- Lactation (use only if potential benefit justifies risks to fetus)
Pregnancy Category:C
Breastfeeding: Safety unknown; it should not be administered during nursing unless the potential benefit outweighs the potential risk to the fetus.
Pricing data from www.DrugStore.com in U.S.A.
- Toviaz 4 MG TB24 [Bottle] (PFIZER U.S.)
30 mg = $156.99
90 mg = $446.98 - Toviaz 8 MG TB24 [Bottle] (PFIZER U.S.)
30 mg = $156.99
90 mg = $446.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: 24 HR Toviaz 4 MG Extended Release Tablet
Ingredient(s): Fesoterodine
Imprint: FS
Color(s): Blue
Shape: Oval
Size (mm): 13.00
Score: 1
Inactive Ingredient(s): glyceryl behenate / hypromellose / indigotindisulfonate sodium / aluminum oxide / lactose monohydrate / lecithin, soybean / cellulose, microcrystalline / polyethylene glycol / polyvinyl alcohol / talc / titanium dioxide / xylitol
Drug Label Author:
Pfizer Laboratories Div Pfizer Inc
DEA Schedule:
Non-Scheduled
Drug Name: 24 HR Toviaz 8 MG Extended Release Tablet
Ingredient(s): Fesoterodine
Imprint: FT
Color(s): Blue
Shape: Oval
Size (mm): 13.00
Score: 1
Inactive Ingredient(s): glyceryl behenate / hypromellose / indigotindisulfonate sodium / aluminum oxide / lactose monohydrate / lecithin, soybean / cellulose, microcrystalline / polyethylene glycol / polyvinyl alcohol / talc / titanium dioxide / xylitol
Drug Label Author:
Pfizer Laboratories Div Pfizer Inc
DEA Schedule:
Non-Scheduled
